Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
O15120

UPID:
PLCB_HUMAN

ALTERNATIVE NAMES:
1-acylglycerol-3-phosphate O-acyltransferase 2; Lysophosphatidic acid acyltransferase beta

ALTERNATIVE UPACC:
O15120; O00516; O15106; Q5VUD3; Q5VUD4; Q9BSV7; Q9BWR7

BACKGROUND:
1-acyl-sn-glycerol-3-phosphate acyltransferase beta, alternatively known as Lysophosphatidic acid acyltransferase beta, is pivotal in converting LPA to PA, essential for lipid synthesis. This enzyme's activity influences the production of critical cellular lipids.

THERAPEUTIC SIGNIFICANCE:
Linked to Congenital generalized lipodystrophy 1, characterized by extreme insulin resistance and early-onset diabetes, this protein's study offers insights into potential therapeutic avenues for managing lipid metabolism disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.